I. Fearen

发表

A phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other leukemias.

J. Aster, L. Silverman, W. Stock, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma

Linda Z Sun, K. Anderson, C. Mitsiades, 2008, Leukemia & lymphoma.

Long-term follow-up of trauma patients with a vena caval filter.

M. Pasquale, M. Cipolle, J. Jaffe, 2000, The Journal of trauma.

Phase I pharmacokinetic (PK), and pharmacodynamic (PD) trial of the novel oral Notch inhibitor MK-0752 in patients (pts) with advanced breast cancer (BC) and other solid tumors.

E. Winer, P. LoRusso, M. Kosh, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-in-class phase I trial of a selective Akt inhibitor, MK2206 (MK), evaluating alternate day (QOD) and once weekly (QW) doses in advanced cancer patients (pts) with evidence of target modulation and antitumor activity.

A. Tolcher, N. Tunariu, K. Papadopoulos, 2010 .

Final results of a translational phase l study assessing a QOD schedule of the potent AKT inhibitor MK-2206 incorporating predictive, pharmacodynamic (PD), and functional imaging biomarkers.

A. Tolcher, N. Tunariu, A. Patnaik, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

LONG-TERM FOLLOW-UP OF TRAUMA PATIENTS WITH A VENA CAVAL FILTER

M. Pasquale, M. Cipolle, J. Jaffe, 1999 .

A phase I study of MK-2206, an oral potent allosteric Akt inhibitor (Akti), in patients (pts) with advanced solid tumor (ST).

A. Tolcher, K. Papadopoulos, M. Beeram, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Interrogating Two Schedules of the AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors Incorporating Novel Pharmacodynamic and Functional Imaging Biomarkers

Martin O. Leach, Nina Tunariu, Robert A. Beckman, 2014, Clinical Cancer Research.

First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.

David Olmos, A. Tolcher, K. Papadopoulos, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I clinical trial of an allosteric AKT inhibitor, MK-2206, using a once weekly (QW) dose regimen in patients with advanced solid tumors.

A. Tolcher, A. Patnaik, M. Garrett, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Final Results of a Phase I Trial of Oral Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Patients with Advanced Multiple Myeloma.

Linda Z Sun, D. Siegel, P. Richardson, 2007 .